NYRADA INC.

0.00%

11.0¢

Market Cap $23.13M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Latest Threads

Tag

Subject

NYR

Ann: Results of Meeting

17/04/25

630

17/04/25

Last post Old Red

630

NYR

Ann: Quarterly Activities Report and Appendix 4C

15/04/25

474

15/04/25

Last post

ASX News

474

NYR

Ann: Notice of Initial Substantial Holder - M Azzi

14/04/25

6.4K

14/04/25

Last post

kates9999

6.4K

NYR

Ann: Phase I Clinical Trial Dosing Update No 1

09/04/25

2.2K

09/04/25

Last post Bendunstan

2.2K

NYR

Ann: Significant Neuroprotection in Traumatic Brain Injury Study

09/04/25

5.2K

09/04/25

Last post Itchybeaver

5.2K

NYR

Study finds Nyrada's lead drug can prevent secondary brain injury

07/04/25

286

07/04/25

Last post ASX Insights

286

NYR

Ann: First Cohort Dosed in Nyradas Phase I Clinical Trial

07/04/25

6.7K

07/04/25

Last post Bendunstan

6.7K

NYR

Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug

31/03/25

151

31/03/25

Last post

151

See All Discussions

Timeline

Results of Meeting
17 Apr 10:42	Share

Quarterly Activities Report and Appendix 4C
15 Apr 08:23	Share

Notice of Initial Substantial Holder - M Azzi
09 Apr 16:17	Share

Phase I Clinical Trial Dosing Update No 1
09 Apr 08:22	Share

Significant Neuroprotection in Traumatic Brain Injury Study
07 Apr 08:27	Share

First Cohort Dosed in Nyradas Phase I Clinical Trial
31 Mar 09:52	Share

Nyrada Commences Phase I Clinical Trial Recruitment
17 Mar 09:19	Share

2025 EGM Letter to Shareholders, Notice of Meeting and Proxy
12 Mar 08:25	Share

Nyrada Half Year Results FY2025
18 Feb 14:15	Share

Appendix 4D and Half Year Report to 31 December 2024
18 Feb 14:11	Share

Nyrada to Commence Phase Ia Clinical Trial
07 Feb 11:49	Share

Quarterly Activities Report and Appendix 4C
23 Jan 11:23	Share

Change of Director's Interest Notice - JM
23 Jan 08:20	Share

Change of Director's Interest Notice - MF
22 Jan 08:29	Share

Change of Director's Interest Notice - RW
22 Jan 08:29	Share

Change of Director's Interest Notice - CC
22 Jan 08:29	Share

Change of Director's Interest Notice - ID
21 Jan 17:15	Share

Notification of cessation of securities - NYR
21 Jan 16:56	Share

NYR-BI03 Phase Ia Clinical Trial Update 2
31 Dec 08:46	Share

Nyrada Receives A$1.235M R&D Tax Incentive Rebate
24 Dec 08:25	Share

Upcoming Expiry of Unlisted Warrants
23 Dec 08:27	Share

NYR-BI03 Phase Ia Clinical Trial Update - Correction
17 Dec 08:14	Share

NYR-BI03 Phase Ia Clinical Trial Update
16 Dec 16:42	Share

Application for quotation of securities - NYR
09 Dec 09:48	Share

Securities Purchase Plan Closure
06 Dec 16:44	Share

Investor Presentation
25 Nov 08:24	Share

Nyrada Investor Conference Call Reminder
25 Nov 08:23	Share

Change of Director's Interest Notice - GM
14 Nov 09:13	Share

Notification regarding unquoted securities - NYR
14 Nov 09:08	Share

Nyrada Annual General Meeting Results
12 Nov 11:22	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 11.0¢		Change 0.000(0.00%)		Mkt cap ! $23.13M

Open	High	Low	Value	Volume
11.0¢	12.0¢	11.0¢	$5.132K	45.52K

Buyers (Bids)

No.	Vol.	Price($)
1	683	11.0¢

Sellers (Offers)

Price($)	Vol.	No.
12.0¢	29213	2

View Market Depth

No.	Vol.	Price($)
1	683	0.110
2	147476	0.105
5	232000	0.100
2	520408	0.098
1	25000	0.097

Price($)	Vol.	No.
0.120	29213	2
0.125	114740	3
0.130	200000	1
0.135	100000	1
0.140	86000	3

Last trade - 13.58pm 18/04/2025 (20 minute delay)

NYR (ASX) Chart

NYRADA INC.

Latest Threads

Download your free Thematic Insights report HERE

Timeline

Featured News

Latest Articles

Study finds Nyrada's lead drug can prevent secondary brain injury

Nyrada Inc has reported strong results from a collaborative study it has been engaged in regarding its lead candidate NYR-BI03

Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug

Nyrada Inc has dosed the first cohort of patients in its Phase I first-in-human trial to assess the safety and tolerability of NYR-BI03

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Nyrada Inc has completed an in-vivo micronucleus on the effects of its NYR-BI03 drug on rats, suggesting it causes no genetic damage

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News